QLi5 Therapeutics

Next Generation Proteasome inhibitors for unmet medical needs deployed by an international Research & Development Network

Next Generation Proteasome Inhibitors

A new class of proteasome inhibitors with a unprecedented, non-covalent mode of action has been developed in close collaboration with Prof. Robert Huber from the Max Planck Institute for Biochemistry.

QLi5 compounds should allow application in wide range of application due to

Platform Technology for unmet medical needs

QLi5 Compounds show strong anti-tumor activity against multiple myeloma and solid tumors.

Novel series of non-covalent proteasome inhibitors

No accumulation in blood cells

Good tissue distribution

Hematologic malignancies

Inflammation & Autoimmune diseas